Deubiquitination of SARM1 by USP13 regulates SARM1 activation and axon degeneration

Abstract

Sterile alpha and Toll/interleukin 1 receptor motif-containing protein 1 (SARM1) is regarded as a key protein and a central executor of the self-destruction of injured axons. To identify novel molecular players and understand the mechanisms regulating SARM1 function, we investigated the interactome of SARM1 by proximity labeling and proteomic profiling. Among the SARM1-associated proteins, we uncovered that overexpression (OE) of ubiquitin-specific peptidase 13 (USP13) delayed injury-induced axon degeneration. OE of an enzyme-dead USP13 failed to protect injured axons, indicating that the deubiquitinase activity of USP13 was required for its axonal protective effect. Further investigation revealed that USP13 deubiquitinated SARM1, which increased the inhibitory interaction between the N-terminal armadillo repeat motif (ARM) and C-terminal Toll/interleukin-1 receptor (TIR) domains of the SARM1 protein, thereby suppressing SARM1 activation in axon injury. Collectively, these findings suggest that increase of USP13 activity enhances the self-inhibition of SARM1, which may provide a strategy to mitigate axon degeneration in injury and disease.

Keywords

axon injury / Wallerian degeneration / SARM1 / USP13 / deubiquitination

References

[1] Ding C, Hammarlund M. Mechanisms of injury-induced axon degeneration. Curr Opin Neurobiol 2019;57:171–8.

[2] Coleman MP, Höke A. Programmed axon degeneration: from mouse to mechanism to medicine. Nat Rev Neurosci 2020;21:183–96.

[3] Zhang K, Jiang M, Fang Y. The drama of wallerian degeneration: the cast, crew, and script. Annu Rev Genet 2021;55:93–113.

[4] Osterloh JM, Yang J, Rooney TM et al. dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science 2012;337:481–4.

[5] Gerdts J, Summers DW, Sasaki Y et al. Sarm1-mediated axon degeneration requires both SAM and TIR interactions. J Neurosci 2013;33:13569–80.

[6] Krauss R, Bosanac T, Devraj R et al. Axons matter: the promise of treating neurodegenerative disorders by targeting SARM1-mediated axonal degeneration. Trends Pharmacol Sci 2020;41:281–93.

[7] Loring HS, Thompson PR. Emergence of SARM1 as a potential therapeutic target for Wallerian-type diseases. Cell Chem Biol 2020;27:1–13.

[8] Lu Q, Botchway BOA, Zhang Y et al. SARM1 can be a potential therapeutic target for spinal cord injury. Cell Mol Life Sci 2022;79:161.

[9] Gerdts J, Brace EJ, Sasaki Y et al. SARM1 activation triggers axon degeneration locally via NAD⁺ destruction. Science 2015;348:453–7.

[10] Essuman K, Summers DW, Sasaki Y et al. The SARM1 toll/interleukin-1 receptor domain possesses intrinsic NAD+ cleavage activity that promotes pathological axonal degeneration. Neuron 2017;93:1334–1343.e5.

[11] Essuman K, Summers DW, Sasaki Y et al. TIR domain proteins are an ancient family of NAD+-consuming enzymes. Curr Biol 2018;28:421–430.e4.

[12] Wan L, Essuman K, Anderson RG et al. TIR domains of plant immune receptors are NAD+-cleaving enzymes that promote cell death. Science 2019;365:799–803.

[13] Gerdts J, Summers DW, Milbrandt J et al. Axon self-destruction: new links among SARM1, MAPKs, and NAD+ metabolism. Neuron 2016;89:449–60.

[14] Figley MD, DiAntonio A. The SARM1 axon degeneration pathway: control of the NAD+ metabolome regulates axon survival in health and disease. Curr Opin Neurobiol 2020;63:59–66.

[15] Bratkowski M, Xie T, Thayer DA et al. Structural and mechanistic regulation of the pro-degenerative NAD hydrolase SARM1. Cell Rep 2020;32:107999.

[16] Jiang Y, Liu T, Lee CH et al. The NAD+-mediated self-inhibition mechanism of pro-neurodegenerative SARM1. Nature 2020;588:658–63.

[17] Shen C, Vohra M, Zhang P et al. Multiple domain interfaces mediate SARM1 autoinhibition. Proc Natl Acad Sci USA 2021;118:e2023151118.

[18] Murata H, Khine CC, Nishikawa A et al. c-Jun N-terminal kinase (JNK)-mediated phosphorylation of SARM1 regulates NAD+ cleavage activity to inhibit mitochondrial respiration. J Biol Chem 2018;293:18933–43.

[19] Figley MD, Gu W, Nanson JD et al. SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration. Neuron 2021;109:1118–1136.e11.

[20] Shi Y, Kerry PS, Nanson JD, et al. Structural basis of SARM1 activation, substrate recognition, and inhibition by small molecules. Mol Cell 2022;82:1643–1659.e10.

[21] Hung V, Udeshi ND, Lam SS et al. Spatially resolved proteomic mapping in living cells with the engineered peroxidase APEX2. Nat Protoc 2016;11:456–75.

[22] Panneerselvam P, Singh LP, Selvarajan V et al. T-cell death following immune activation is mediated by mitochondria-localized SARM. Cell Death Differ 2013;20:478–89.

[23] Murata H, Sakaguchi M, Kataoka K et al. SARM1 and TRAF6 bind to and stabilize PINK1 on depolarized mitochondria. Mol Biol Cell 2013;24:2772–84.

[24] Liu Y, Soetandyo N, Lee JG et al. USP13 antagonizes gp78 to maintain functionality of a chaperone in ER-associated degradation. Elife 2014;3:e01369.

[25] Liu X, Moussa C. Regulatory role of ubiquitin specific protease-13 (USP13) in misfolded protein clearance in neurodegenerative diseases. Neuroscience 2021;460:161–6.

[26] Wang Q, Sun Z, Xia W et al. Role of USP13 in physiology and diseases. Front Mol Biosci 2022;9:977122.

[27] Li X, Yang G, Zhang W et al. USP13: Multiple functions and target inhibition. Front Cell Dev Biol 2022;10:875124.

[28] Sun H, Zhang Q, Jing YY et al. USP13 negatively regulates antiviral responses by deubiquitinating STING. Nat Commun 2017;8:15534.

[29] Reyes-Turcu FE, Ventii KH, Wilkinson KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 2009;78:363–97.

[30] Liu J, Xia H, Kim M et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 2011;147:223–34.

[31] Summers DW, Gibson DA, DiAntonio A et al. SARM1-specific motifs in the TIR domain enable NAD+ loss and regulate injury-induced SARM1 activation. Proc Natl Acad Sci USA 2016;113:E6271–80.

[32] Wakatsuki S, Saitoh F, Araki T. ZNRF1 promotes Wallerian degeneration by degrading AKT to induce GSK3B-dependent CRMP2 phosphorylation. Nat Cell Biol 2011;13:1415–23.

[33] Wakatsuki S, Tokunaga S, Shibata M et al. GSK3B-mediated phosphorylation of MCL1 regulates axonal autophagy to promote Wallerian degeneration. J Cell Biol 2017;216:477–93.

[34] Yang J, Wu Z, Renier N et al. Pathological axonal death through a MAPK cascade that triggers a local energy deficit. Cell 2015;160:161–76.

[35] Xue T, Sun Q, Zhang Y et al. Phosphorylation at S548 as a functional switch of sterile alpha and TIR motif-containing 1 in cerebral ischemia/reperfusion injury in rats. Mol Neurobiol 2021;58:453–69.

[36] Ehlers MD. Deconstructing the axon: Wallerian degeneration and the ubiquitin-proteasome system. Trends Neurosci 2004;27:3–6.

[37] Zhai Q, Wang J, Kim A et al. Involvement of the ubiquitin-proteasome system in the early stages of wallerian degeneration. Neuron 2003;39:217–25.

[38] Xiong X, Hao Y, Sun K et al. The Highwire ubiquitin ligase promotes axonal degeneration by tuning levels of Nmnat protein. PLoS Biol 2012;10:e1001440.

[39] Babetto E, Beirowski B, Russler EV et al. The Phr1 ubiquitin ligase promotes injury-induced axon self-destruction. Cell Rep 2013;3:1422–9.

[40] Yamagishi Y, Tessier-Lavigne M. An Atypical SCF-like ubiquitin ligase complex promotes Wallerian degeneration through regulation of axonal Nmnat2. Cell Rep 2016;17:774–82.

[41] Desbois M, Crawley O, Evans PR et al. PAM forms an atypical SCF ubiquitin ligase complex that ubiquitinates and degrades NMNAT2. J Biol Chem 2018;293:13897–909.

[42] Summers DW, Milbrandt J, DiAntonio A. Palmitoylation enables MAPK-dependent proteostasis of axon survival factors. Proc Natl Acad Sci USA 2018;115:E8746–54.

[43] Milde S, Gilley J, Coleman MP. Subcellular localization determines the stability and axon protective capacity of axon survival factor Nmnat2. PLoS Biol 2013;11:e1001539.

[44] Thornburg-Suresh EJC, Richardson JE, Summers DW. The Stathmin-2 membrane-targeting domain is required for axon protection and regulated degradation by DLK signaling. J Biol Chem 2023;299:104861.

[45] Suzuki K, Koike T. Mammalian Sir2-related protein (SIRT) 2- mediated modulation of resistance to axonal degeneration in slow Wallerian degeneration mice: a crucial role of tubulin deacetylation. Neuroscience 2007;147:599–612.

[46] Chen Y, Akin O, Nern A et al. Cell-type-specific labeling of synapses in vivo through synaptic tagging with recombination. Neuron 2014;81:280–93.

[47] Sun X, Duan Y, Qin C et al. Distinct multilevel misregulations of Parkin and PINK1 revealed in cell and animal models of TDP-43 proteinopathy. Cell Death Dis 2018;9:953.

[48] Tyanova S, Temu T, Sinitcyn P et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods 2016;13:731–40.

[49] Kim Y, Zhou P, Qian L et al. MyD88-5 links mitochondria, microtubules, and JNK3 in neurons and regulates neuronal survival. J Exp Med 2007;204:2063–74.

[50] Wang L, Marquardt T. Direct live monitoring of heterotypic axon-axon interactions in vitro. Nat Protoc 2012;7:351–63.

RIGHTS & PERMISSIONS

2023 The Author(s) 2023. Published by Oxford University Press on behalf of Higher Education Press.